Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.
Saved in:
| Title: | Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto. |
|---|---|
| Authors: | Chow V; Amgen Inc., Thousand Oaks, California, USA., Zhou M; Amgen Inc., Thousand Oaks, California, USA., Mytych DT; Amgen Inc., Thousand Oaks, California, USA., Colbert A; Amgen Inc., Thousand Oaks, California, USA., Miller MJ; Amgen Inc., Thousand Oaks, California, USA., Wala I; Amgen Inc., Thousand Oaks, California, USA., Sabet A; Icon, Salt Lake City, Utah, USA., Radziszewski W; Amgen Inc., Thousand Oaks, California, USA. |
| Source: | Pharmacology research & perspectives [Pharmacol Res Perspect] 2026 Apr; Vol. 14 (2), pp. e70236. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101626369 Publication Model: Print Cited Medium: Internet ISSN: 2052-1707 (Electronic) Linking ISSN: 20521707 NLM ISO Abbreviation: Pharmacol Res Perspect Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2052-1707 |
|---|---|
| DOI: | 10.1002/prp2.70236 |
